Monday 1 July 2024

The Pharma Letter Podcast — Episode 9 — The rise of AI in drug discovery

Biotechnology
Simon Wentworth
30 December 2021
episode9-theriseofai

More on this story...

Pharmaceutical
European drugmakers embrace artificial intelligence
3 December 2020
Pharmaceutical
Global regulators rise to meet artificial intelligence challenge
16 August 2021
Biotechnology
Absci rockets as it inks AI research deal with Merck
8 January 2022
Biotechnology
Biolojic Design inks multi-target drug collaboration with Merck
4 June 2024


Related Company News

BioMed X Institute enters new collaboration with Merck
BioMed X institute and Merck KGaA extend cancer collaboration
BioMed X expands its collaboration with Merck KGaA
BRIEF—Schizophrenia focus for latest Boehringer and BioMed X tie-up
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze